Takeda Pharmaceutical, Japan’s major pharmaceutical company, surpassed analysts’ expectations with a strong first-quarter profit. The company attributed its success to solid sales of core drugs and the successful launch of new products, notably its dengue fever vaccine. Despite facing challenges as some of its main revenue-generating drugs lost patent protection, Takeda remains optimistic as it works to find new successes in its drug pipeline. Operating profit rose by 12% year-on-year to 168.6 billion yen ($1.2 billion) in the three months through June 30, outperforming analysts’ average forecast. Takeda maintained its full-year operating profit forecast at 349 billion yen, while analysts expected an average of 481.1 billion yen for the year. Recent acquisitions and regulatory approvals also bode well for the company’s future growth prospects.
Global News and Digital Insights
for the Healthcare Industry
Menu
